{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:26:39Z","timestamp":1794641199835,"version":"4.9.1"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002370"],"award-info":[{"award-number":["KL2TR002370"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA224019"],"award-info":[{"award-number":["U54CA224019"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA271412"],"award-info":[{"award-number":["U01CA271412"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA262758"],"award-info":[{"award-number":["R01CA262758"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Resistance to venetoclax (VEN)-based therapy in acute myeloid leukemia (AML) includes genetic (i.e., mutations in N\/KRAS, FLT3-ITD, TP53) and phenotypic (i.e., monocytic differentiation) features. Whether monocytic differentiation contributes to clinical VEN resistance secondary to a genetic bias remains unknown. This multimodal, multicenter, international analysis, inclusive of 678 patients, comprehensively characterized the prognostic role of monocytic differentiation in patients with AML treated with hypomethylating agents combined with VEN. AML genetics and monocytic differentiation (HR = 1.89; 95% confidence interval, 1.35\u20132.66; P &amp;lt; 0.001) in NPM1 wild-type cases correlated with an increased risk of death, clustering of centralized quantitative multiparameter flow cytometry data, evaluation of RNA sequencing-derived AML maturation stage, and single-cell proteogenomics linked driver mutations with AML phenotype and antiapoptotic gene expression. This comprehensive analysis of AML genetics, phenotype, and antiapoptotic protein expression highlights the complementary role these factors impart following VEN-based therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>AML with monocytic differentiation often occurs in the context of co-occurring mutations within signaling pathways. In certain AML subgroups (such as NPM1 wild-type and signaling pathway gene\u2013mutated), a monocytic phenotype is associated with decreased overall survival following VEN-based therapy.<\/jats:p>\n                    <jats:p>See related commentary by Renders, p. 403<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0256","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T10:02:02Z","timestamp":1747821722000},"page":"437-449","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-0624","authenticated-orcid":false,"given":"Curtis A.","family":"Lachowiez","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-8657","authenticated-orcid":false,"given":"Mael","family":"Heiblig","sequence":"additional","affiliation":[{"name":"2D\u00e9partement d\u2019h\u00e9matologie clinique, Hopital Lyon Sud, Pierre B\u00e9nite, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-575X","authenticated-orcid":false,"given":"Gaspar","family":"Aspas Requena","sequence":"additional","affiliation":[{"name":"3Service d\u2019h\u00e9matologie clinique et th\u00e9rapie cellulaire, CHU Clermont-Ferrand, Clermont-Ferrand, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-8721","authenticated-orcid":false,"given":"Emmanuelle","family":"Tavernier-Tardy","sequence":"additional","affiliation":[{"name":"4D\u00e9partement d\u2019h\u00e9matologie clinique, Institut de Canc\u00e9rologie de Loire, Saint Priest en Jarez, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-4547","authenticated-orcid":false,"given":"Fangyan","family":"Dai","sequence":"additional","affiliation":[{"name":"5Hematologics, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6911-9061","authenticated-orcid":false,"given":"Amenech B.","family":"Ashango","sequence":"additional","affiliation":[{"name":"5Hematologics, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-0994","authenticated-orcid":false,"given":"Daniel T.","family":"Peters","sequence":"additional","affiliation":[{"name":"6Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4422-1449","authenticated-orcid":false,"given":"Jacob","family":"Fang","sequence":"additional","affiliation":[{"name":"7Division of Hematology, School of Medicine, University of Colorado, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9425-6936","authenticated-orcid":false,"given":"Andy","family":"Kaempf","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-8167","authenticated-orcid":false,"given":"Nicola","family":"Long","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8835-8928","authenticated-orcid":false,"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-389X","authenticated-orcid":false,"given":"Stephen E.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-7666","authenticated-orcid":false,"given":"Wei","family":"Xie","sequence":"additional","affiliation":[{"name":"8Department of Pathology and Laboratory Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8319-6162","authenticated-orcid":false,"given":"Anupriya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-8135","authenticated-orcid":false,"given":"Aishwarya","family":"Sahasrabudhe","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-9595","authenticated-orcid":false,"given":"Christine M.","family":"McMahon","sequence":"additional","affiliation":[{"name":"7Division of Hematology, School of Medicine, University of Colorado, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-5019","authenticated-orcid":false,"given":"Maria L.","family":"Amaya","sequence":"additional","affiliation":[{"name":"7Division of Hematology, School of Medicine, University of Colorado, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-8745","authenticated-orcid":false,"given":"Gabrielle","family":"Meyers","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9762-8069","authenticated-orcid":false,"given":"Arpita","family":"Gandhi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-0048","authenticated-orcid":false,"given":"Jessica","family":"Leonard","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-4573","authenticated-orcid":false,"given":"Brandon","family":"Hayes-Lattin","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-2345","authenticated-orcid":false,"given":"Elie","family":"Traer","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7005-036X","authenticated-orcid":false,"given":"Rachel J.","family":"Cook","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-1870","authenticated-orcid":false,"given":"Ronan","family":"Swords","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-2143","authenticated-orcid":false,"given":"Theodore P.","family":"Braun","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-9466","authenticated-orcid":false,"given":"Jennifer N.","family":"Saultz","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-4965","authenticated-orcid":false,"given":"Ashley M.","family":"Eckel","sequence":"additional","affiliation":[{"name":"5Hematologics, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0335-9065","authenticated-orcid":false,"given":"Michael R.","family":"Loken","sequence":"additional","affiliation":[{"name":"5Hematologics, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1514","authenticated-orcid":false,"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[{"name":"6Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-0960","authenticated-orcid":false,"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[{"name":"7Division of Hematology, School of Medicine, University of Colorado, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"2025100710270087300_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100710270087300_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"2025100710270087300_bib3","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"2025100710270087300_bib4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"2025100710270087300_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"2025100710270087300_bib6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100710270087300_bib7","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","article-title":"Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia","volume":"108","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Haematologica"},{"key":"2025100710270087300_bib8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"key":"2025100710270087300_bib9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat Med"},{"key":"2025100710270087300_bib10","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100710270087300_bib11","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100710270087300_bib12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"2025100710270087300_bib13","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"2025100710270087300_bib14","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov"},{"key":"2025100710270087300_bib15","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"key":"2025100710270087300_bib16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"2025100710270087300_bib17","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"issue":"Suppl 1","key":"2025100710270087300_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-138580","article-title":"Outcomes of de novo acute myeloid leukemia with monocytic differentiation (FAB M4\/5) treated with venetoclax and decitabine","volume":"136","author":"Maiti","year":"2020","journal-title":"Blood"},{"key":"2025100710270087300_bib19","doi-asserted-by":"crossref","first-page":"e160928c","DOI":"10.1097\/01.HS9.0000968992.16092.8c","article-title":"P521: findings from an analysis of patients with monocytic and monocytic-like acute myeloid leukemia (AML), including AML-M4 and AML-M5, treated with venetoclax (VEN) plus azacitidine (AZA)","volume":"7","author":"Konopleva","year":"2023","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"2025100710270087300_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2023-187695","article-title":"N\/KRAS-Mutant AML lSCs originate from committed myelomonocytic progenitors and drive clinical resistance to venetoclax","volume":"142","author":"Sango","year":"2023","journal-title":"Blood"},{"key":"2025100710270087300_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"2025100710270087300_bib22","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"2025100710270087300_bib23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"key":"2025100710270087300_bib24","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"key":"2025100710270087300_bib25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"key":"2025100710270087300_bib26","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"key":"2025100710270087300_bib27","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"2025100710270087300_bib28","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2025100710270087300_bib29","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"key":"2025100710270087300_bib30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00277-024-05646-7","article-title":"Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann Hematol"},{"key":"2025100710270087300_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am J Hematol"},{"key":"2025100710270087300_bib32","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100710270087300_bib33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26731","article-title":"Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes","volume":"97","author":"Rivera","year":"2022","journal-title":"Am J Hematol"},{"key":"2025100710270087300_bib34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2025100710270087300_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax\u00b1azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2025100710270087300_bib36","doi-asserted-by":"crossref","first-page":"101585","DOI":"10.1016\/j.xcrm.2024.101585","article-title":"Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia","volume":"5","author":"Montalban-Bravo","year":"2024","journal-title":"Cell Rep Med"},{"key":"2025100710270087300_bib37","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/bloodadvances.2024012880","article-title":"Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era","volume":"8","author":"Patel","year":"2024","journal-title":"Blood Adv"},{"key":"2025100710270087300_bib38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"2025100710270087300_bib39","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0256\/3606919\/bcd-24-0256.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0256\/3634026\/bcd-24-0256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/5\/437\/3646181\/bcd-24-0256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/5\/437\/3646181\/bcd-24-0256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:27:20Z","timestamp":1759847240000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/5\/437\/764330\/Genetic-and-Phenotypic-Correlates-of-Clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,21]]},"published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0256","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.30040824","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040836","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040833","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040845","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040839","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040848","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040827","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296472","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296463","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296475","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296481","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296460","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296469","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040842","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296454","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040821","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296466","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296478","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30040830","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30296457","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8014455","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}